TY - JOUR
T1 - Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia
AU - Teipel, Stefan
AU - König, Alexandra
AU - Hoey, Jesse
AU - Kaye, Jeff
AU - Krüger, Frank
AU - Robillard, Julie M.
AU - Kirste, Thomas
AU - Babiloni, Claudio
N1 - Funding Information:
S.T. is supported by grants from the Federal Ministry of Research (BMBF), Germany, (01GQ1425B, 16SV7091, 16SV7348K) and the Marie-S. Curie Innovative Training Network BBDiag (EU-Horizon2020 Project ID: 721281). C.B. is supported by the Marie- S. Curie Innovative Training Network BBDiag as well. J.K. is supported by grants from the National Institute on Aging (R01 AG042191, P30AG024978, P30AG008017, U2CAG054397). F.K. is supported by the German Research Foundation (DFG), Germany (CRC 1270). T.K. is supported by grants from the Federal Ministry of Research (BMBF), Germany, (16SV7091, 16SV7349, 03ZZ0519D). J.H. is supported by AGE-WELL NCE Inc., the Canadian Consortium on Neurodegeneration and Aging, the Alzheimer's Association (grant number ETAC-14-321494) and the Natural Sciences and Engineering Research Council of Canada (NSERC). J.M.R. is supported by AGE-WELL NCe Inc., and the Canadian Consortium on Neurodegeneration in Aging. A.K. is supported by grants from the European Institute of Innovation & Technology (EIT - Digital Wellbeing Activity 17074) and the European Union's Horizon 2020 research and innovation programme (Project ID: 683356).
Publisher Copyright:
© 2018 The Authors
PY - 2018/9
Y1 - 2018/9
N2 - Cognitive function is an important end point of treatments in dementia clinical trials. Measuring cognitive function by standardized tests, however, is biased toward highly constrained environments (such as hospitals) in selected samples. Patient-powered real-world evidence using information and communication technology devices, including environmental and wearable sensors, may help to overcome these limitations. This position paper describes current and novel information and communication technology devices and algorithms to monitor behavior and function in people with prodromal and manifest stages of dementia continuously, and discusses clinical, technological, ethical, regulatory, and user-centered requirements for collecting real-world evidence in future randomized controlled trials. Challenges of data safety, quality, and privacy and regulatory requirements need to be addressed by future smart sensor technologies. When these requirements are satisfied, these technologies will provide access to truly user relevant outcomes and broader cohorts of participants than currently sampled in clinical trials.
AB - Cognitive function is an important end point of treatments in dementia clinical trials. Measuring cognitive function by standardized tests, however, is biased toward highly constrained environments (such as hospitals) in selected samples. Patient-powered real-world evidence using information and communication technology devices, including environmental and wearable sensors, may help to overcome these limitations. This position paper describes current and novel information and communication technology devices and algorithms to monitor behavior and function in people with prodromal and manifest stages of dementia continuously, and discusses clinical, technological, ethical, regulatory, and user-centered requirements for collecting real-world evidence in future randomized controlled trials. Challenges of data safety, quality, and privacy and regulatory requirements need to be addressed by future smart sensor technologies. When these requirements are satisfied, these technologies will provide access to truly user relevant outcomes and broader cohorts of participants than currently sampled in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85052867258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052867258&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2018.05.003
DO - 10.1016/j.jalz.2018.05.003
M3 - Short survey
C2 - 29936147
AN - SCOPUS:85052867258
SN - 1552-5260
VL - 14
SP - 1216
EP - 1231
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 9
ER -